Visiongain report states: “Global Ophthalmic Devices Market Set To Grow To $47.2bn” By 2022

25 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Ophthalmic Devices Market 2018-2028: Vision Care, Surgical, Diagnostics and Monitoring, OCT Machines, Autorefractor/Keratometer, Fundus Camera, Slit Lamp, OR Microscope, Optical Biometry, Tonometer, Perimeter, Cataract Surgery, Refractive Surgery, Vitro Retinal Surgery, Glaucoma Surgery, Spectacles, Contact Lenses, Daily Disposables

The medical devices industry is one of the largest and fastest growing markets in the medical and pharmaceutical industries. Rise in geriatric population has led to a rise in ophthalmic conditions such as cataract and diabetic retinopathy. Moreover, rising disposable income, growing awareness of ophthalmic conditions coupled with favourable reimbursement policies of government will further boost the overall growth of ophthalmic surgical devices market.

The lead analyst of the report commented “Global ophthalmic devices market is driven by innovation, launch of innovative and user-friendly products having advanced technology leads to replacement of the conventional techniques and devices. The market is highly consolidated with very few international players competing with each other head to head. Moreover, high entry and exit barriers are increasing the degree of competitive rivalry among existing players.

The overall power of suppliers in the ophthalmic devices market is low, due to a high level of fragmentation. Medical device companies are increasingly outsourcing their manufacturing, and R&D, to a growing number of contract manufacturers in order to become more cost competitive.”

Leading companies featured in the report include Abbott Medical Optics (AMO), Alcon, Bausch and Lomb (B&L), Carl Zeiss AG Meditec, Haag-Streit Holding AG, Hoya, Johnson & Johnson (J&J), Nidek, STAAR, TopCon, Zeimer Ophthalmic Solutions.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever